Top

Published in:

01-07-2016 | Original Article

MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma

Authors: Xiao-Pin Ma, Guopeng Yu, Xubo Chen, Qianyi Xiao, Zhuqing Shi, Lu-Yao Zhang, Haitao Chen, Pengyin Zhang, Dong-Lin Ding, Hui-Xing Huang, Hexige Saiyin, Tao-Yang Chen, Pei-Xin Lu, Neng-Jin Wang, Hongjie Yu, Carly Conran, Jielin Sun, S. Lilly Zheng, Jianfeng Xu, Long Yu, De-Ke Jiang

Published in: Tumor Biology | Issue 7/2016

Abstract

Single nucleotide polymorphisms (SNPs) within microRNAs (miRNAs) are considered potential markers for risk and prognosis of various cancers. In the current study, we aimed to determine whether miR-608 rs4919510 affected hepatocellular carcinoma (HCC) prognosis. We genotyped rs4919510 using DNA from blood samples of 362 HCC patients receiving surgical resection of HCC tumor. Associations between rs4919510 and overall survival (OS) and demographic characteristics and clinical features were estimated using the Cox proportional hazards model. Results showed that HCC patients who carried the rs4919510 CC genotype had a significantly longer OS compared to those who carried the GG genotype (P = 0.013, hazard ratio [HR] = 0.600, 95 % confidence interval [CI] 0.402–0.897) and the CG + GG genotype (P = 0.033, HR = 0.681, 95 % CI 0.479–0.970) in univariate analysis. Similar results were obtained in multivariate analysis. Further stratification analysis indicated that rs4919510 was significantly associated with OS in patients who were satisfied with one of the following criteria: male gender, HbsAg-positive, α-fetoprotein (AFP)-positive, tumor size >5 cm, cirrhosis, solitary tumor, I + II pTNM stage, or no tumor capsule. Finally, a significantly higher frequency of rs4919510 CC genotype was observed in patients with cirrhosis (22.9 %, 55/240) than those without cirrhosis (14.0 %, 17/121) (P = 0.047). In conclusion, our results illustrated the potential role of miR-608 rs4919510 as a prognostic marker for HCC patients undergoing surgical resection of the tumor.

Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):448–58. doi:10.1038/nrgastro.2010.100.CrossRefPubMedPubMedCentral

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: Cancer J Clin. 2015. doi:10.3322/caac.21262.

Zhu AX. Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives. Semin Oncol. 2012;39(4):493–502. doi:10.1053/j.seminoncol.2012.05.014.CrossRefPubMed

Schutte K, Schulz C, Link A, Malfertheiner P. Current biomarkers for hepatocellular carcinoma: surveillance, diagnosis and prediction of prognosis. World J Hepatol. 2015;7(2):139–49. doi:10.4254/wjh.v7.i2.139.CrossRefPubMedPubMedCentral

Lee SC, Tan HT, Chung MC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. World J Gastroenterol: WJG. 2014;20(12):3112–24. doi:10.3748/wjg.v20.i12.3112.CrossRefPubMedPubMedCentral

Sala M, Forner A, Varela M, Bruix J. Prognostic prediction in patients with hepatocellular carcinoma. Semin Liver Dis. 2005;25(2):171–80. doi:10.1055/s-2005-871197.CrossRefPubMed

Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13(6):e249–58. doi:10.1016/S1470-2045(12)70073-6.CrossRefPubMed

Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66. doi:10.1038/nrc1997.CrossRefPubMed

Bartel B. MicroRNAs directing siRNA biogenesis. Nat Struct Mol Biol. 2005;12(7):569–71. doi:10.1038/nsmb0705-569.CrossRefPubMed

10.

Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, et al. Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res. 2014;6(4):391–401.PubMedPubMedCentral

11.

Tyagi N, Arora S, Deshmukh SK, Singh S, Marimuthu S, Singh AP. Exploiting nanotechnology for the development of MicroRNA-based cancer therapeutics. J Biomed Nanotechnol. 2016;12(1):28–42. doi:10.1166/jbn.2016.2172.CrossRefPubMed

12.

Duan R, Pak C, Jin P. Single nucleotide polymorphism associated with mature miR-125a alters the processing of pri-miRNA. Hum Mol Genet. 2007;16(9):1124–31. doi:10.1093/hmg/ddm062.CrossRefPubMed

13.

Wu C, Li M, Hu C, Duan H. Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy. Cancer Chemother Pharmacol. 2014;73(2):335–41. doi:10.1007/s00280-013-2364-x.CrossRefPubMed

14.

Pardini B, Rosa F, Naccarati A, Vymetalkova V, Ye Y, Wu X, et al. Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients. Carcinogenesis. 2015;36(1):82–6. doi:10.1093/carcin/bgu224.CrossRefPubMed

15.

Lin M, Gu J, Eng C, Ellis LM, Hildebrandt MA, Lin J, et al. Genetic polymorphisms in microRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res: Off J Am Assoc Cancer Res. 2012;18(14):3982–91. doi:10.1158/1078-0432.CCR-11-2951.CrossRef

16.

Xu T, Zhu Y, Wei QK, Yuan Y, Zhou F, Ge YY, et al. A functional polymorphism in the miR-146a gene is associated with the risk for hepatocellular carcinoma. Carcinogenesis. 2008;29(11):2126–31. doi:10.1093/carcin/bgn195.CrossRefPubMed

17.

Wang R, Zhang J, Ma Y, Chen L, Guo S, Zhang X, et al. Association study of miR149 rs2292832 and miR608 rs4919510 and the risk of hepatocellular carcinoma in a large-scale population. Mol Med Rep. 2014;10(5):2736–44. doi:10.3892/mmr.2014.2536.PubMed

18.

Ryan BM, McClary AC, Valeri N, Robinson D, Paone A, Bowman ED, et al. rs4919510 in hsa-mir-608 is associated with outcome but not risk of colorectal cancer. PLoS ONE. 2012;7(5):e36306. doi:10.1371/journal.pone.0036306.CrossRefPubMedPubMedCentral

19.

Huang AJ, Yu KD, Li J, Fan L, Shao ZM. Polymorphism rs4919510:C > G in mature sequence of human microRNA-608 contributes to the risk of HER2-positive breast cancer but not other subtypes. PLoS ONE. 2012;7(5), e35252. doi:10.1371/journal.pone.0035252.CrossRefPubMedPubMedCentral

20.

Kupcinskas J, Wex T, Link A, Leja M, Bruzaite I, Steponaitiene R, et al. Gene polymorphisms of micrornas in Helicobacter pylori-induced high risk atrophic gastritis and gastric cancer. PLoS ONE. 2014;9(1), e87467. doi:10.1371/journal.pone.0087467.CrossRefPubMedPubMedCentral

21.

Yang PW, Huang YC, Hsieh CY, Hua KT, Huang YT, Chiang TH, et al. Association of miRNA-related genetic polymorphisms and prognosis in patients with esophageal squamous cell carcinoma. Ann Surg Oncol. 2014;21 Suppl 4:S601–9. doi:10.1245/s10434-014-3709-3.CrossRefPubMed

22.

Wei WJ, Wang YL, Li DS, Wang Y, Wang XF, Zhu YX, et al. Association study of single nucleotide polymorphisms in mature microRNAs and the risk of thyroid tumor in a Chinese population. Endocrine. 2015;49(2):436–44. doi:10.1007/s12020-014-0467-8.CrossRefPubMed

23.

Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, et al. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004;23(20):4051–60. doi:10.1038/sj.emboj.7600385.CrossRefPubMedPubMedCentral

24.

Ryan BM, Robles AI, Harris CC. Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer. 2010;10(6):389–402. doi:10.1038/nrc2867.CrossRefPubMedPubMedCentral

25.

Shen J, Ambrosone CB, DiCioccio RA, Odunsi K, Lele SB, Zhao H. A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis. 2008;29(10):1963–6. doi:10.1093/carcin/bgn172.CrossRefPubMed

26.

Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105(20):7269–74. doi:10.1073/pnas.0802682105.CrossRefPubMedPubMedCentral

27.

Okubo M, Tahara T, Shibata T, Yamashita H, Nakamura M, Yoshioka D, et al. Association between common genetic variants in pre-microRNAs and gastric cancer risk in Japanese population. Helicobacter. 2010;15(6):524–31. doi:10.1111/j.1523-5378.2010.00806.x.CrossRefPubMed

28.

Xu B, Feng NH, Li PC, Tao J, Wu D, Zhang ZD, et al. A functional polymorphism in pre-miR-146a gene is associated with prostate cancer risk and mature miR-146a expression in vivo. Prostate. 2010;70(5):467–72. doi:10.1002/pros.21080.PubMed

29.

Hu Z, Chen J, Tian T, Zhou X, Gu H, Xu L, et al. Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest. 2008;118(7):2600–8. doi:10.1172/JCI34934.PubMedPubMedCentral

30.

Qiu F, Yang L, Zhang L, Yang X, Yang R, Fang W, et al. Polymorphism in mature microRNA-608 sequence is associated with an increased risk of nasopharyngeal carcinoma. Gene. 2015;565(2):180–6. doi:10.1016/j.gene.2015.04.008.CrossRefPubMed

31.

Xing J, Wan S, Zhou F, Qu F, Li B, Myers RE, et al. Genetic polymorphisms in pre-microRNA genes as prognostic markers of colorectal cancer. Cancer Epidemiol, Biomark Prev. 2012;21(1):217–27. doi:10.1158/1055-9965.EPI-11-0624.CrossRef

32.

Rah H, Kim HS, Cha SH, Kim YR, Lee WS, Ko JJ, et al. Association of breast cancer-related microRNA polymorphisms with idiopathic primary ovarian insufficiency. Menopause. 2015;22(4):437–43. doi:10.1097/GME.0000000000000325.CrossRefPubMed

33.

Zhang Y, Schiff D, Park D, Abounader R. MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. PLoS ONE. 2014;9(3), e91546. doi:10.1371/journal.pone.0091546.CrossRefPubMedPubMedCentral

34.

Kang JG, Majerciak V, Uldrick TS, Wang X, Kruhlak M, Yarchoan R, et al. Kaposi’s sarcoma-associated herpesviral IL-6 and human IL-6 open reading frames contain miRNA binding sites and are subject to cellular miRNA regulation. J Pathol. 2011;225(3):378–89. doi:10.1002/path.2962.CrossRefPubMedPubMedCentral

35.

Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res. 2014;2(4):288–94. doi:10.1158/2326-6066.CIR-14-0022.CrossRefPubMed

36.

Jeyapalan Z, Deng Z, Shatseva T, Fang L, He C, Yang BB. Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res. 2011;39(8):3026–41. doi:10.1093/nar/gkq1003.CrossRefPubMed

37.

Rutnam ZJ, Yang BB. The non-coding 3′ UTR of CD44 induces metastasis by regulating extracellular matrix functions. J Cell Sci. 2012;125(Pt 8):2075–85. doi:10.1242/jcs100818.CrossRefPubMed

38.

Othman N, In LL, Harikrishna JA, Hasima N. Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells. PLoS ONE. 2013;8(12), e81735. doi:10.1371/journal.pone.0081735.CrossRefPubMedPubMedCentral

39.

Johnson C, Han Y, Hughart N, McCarra J, Alpini G, Meng F. Interleukin-6 and its receptor, key players in hepatobiliary inflammation and cancer. Transl Gastrointest Cancer. 2012;1(1):58–70. doi:10.3978/j.issn.2224-4778.2011.11.02.PubMedPubMedCentral

40.

Liu Y, Fuchs J, Li C, Lin J. IL-6, a risk factor for hepatocellular carcinoma: FLLL32 inhibits IL-6-induced STAT3 phosphorylation in human hepatocellular cancer cells. Cell Cycle. 2010;9(17):3423–7.CrossRefPubMed

41.

Wang Y, van Boxel-Dezaire AHH, Cheon H, Yang J, Stark GR. STAT3 activation in response to IL-6 is prolonged by the binding of IL-6 receptor to EGF receptor. Proc Natl Acad Sci U S A. 2013;110(42):16975–80. doi:10.1073/pnas.1315862110.CrossRefPubMedPubMedCentral

Title: MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma
Authors: Xiao-Pin Ma
Guopeng Yu
Xubo Chen
Qianyi Xiao
Zhuqing Shi
Lu-Yao Zhang
Haitao Chen
Pengyin Zhang
Dong-Lin Ding
Hui-Xing Huang
Hexige Saiyin
Tao-Yang Chen
Pei-Xin Lu
Neng-Jin Wang
Hongjie Yu
Carly Conran
Jielin Sun
S. Lilly Zheng
Jianfeng Xu
Long Yu
De-Ke Jiang
Publication date: 01-07-2016
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-016-4897-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2016

Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis

Alpinetin targets glioma stem cells by suppressing Notch pathway

Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma

Prognostic impact and potential interaction of EGFR and c-Met in the progression of esophageal squamous cell carcinoma

High TXNDC5 expression predicts poor prognosis in renal cell carcinoma

PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer